The Nlrp3 inflammasome admits defeat

doi:10.1016/j.it.2015.05.001

Trends in Immunology

Volume 36, Issue 6, June 2015, Pages 323-324

https://doi.org/10.1016/j.it.2015.05.001 Get rights and content

The Nlrp3 inflammasome triggers interleukin-1 secretion by myeloid cells in response to endogenous and exogenous danger signals. Two recent studies identified the sulfonylurea MCC950 and the ketone metabolite β-hydroxybutyrate as specific inhibitors of the Nlrp3 inflammasome, with promising therapeutic potential for the treatment of auto-inflammatory diseases.

Section snippets

Acknowledgements

Work in the laboratory of O.G. is funded by an ERC Starting Grant and by the Bavarian Ministry of Sciences, Research and the Arts in the Framework of the Bavarian Molecular Biosystems Research Network.

References (10)

R.E. Laliberte
Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing
J. Biol. Chem.
(2003)
X. Cai
Prion-like Polymerization Underlies Signal Transduction in Antiviral Immune Defense and Inflammasome Activation
Cell
(2014)
R. Muñoz-Planillo
K+ Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter
Immunity
(2013)
C. Juliana
Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the Inflammasome
J. Biol. Chem.
(2010)
R.C. Coll
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Nat. Med.
(2015)

There are more references available in the full text version of this article.

Cited by (0)

View full text

Trends in Immunology

SpotlightThe Nlrp3 inflammasome admits defeat

Section snippets

Acknowledgements

J. Biol. Chem.

Cell

Immunity

J. Biol. Chem.

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

Nat. Med.

Spotlight
The Nlrp3 inflammasome admits defeat